Jaykay Enterprises Other Announcement

Results Update

Jaykay Enterprises Results Update

Jaykay Enterprises issued an investor release on Q2 and H1 FY2026-27 results, citing income growth. Highlights include defence orders, medical implant approvals and AI platform progress.

Financial Results

Jaykay Enterprises Q2 FY27 Results: Net Profit ₹8.7 Cr, Down 1.1% YoY

Jaykay Enterprises Ltd reported revenue from operations of ₹93.3 Cr (+47.9% YoY) and net profit of ₹8.7 Cr (-1.1% YoY) for Q2 FY27.

Key figure

Net profit ₹8.7 Cr · -1.1% YoY

Board Meeting Date

Jaykay Enterprises Board Meeting Date

Jaykay Enterprises will hold a board meeting on 13 November 2026 to consider unaudited half-yearly results. Trading window stays closed until 15 November 2026.

Regulatory ApprovalAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Jaykay Enterprises Regulatory Approval

JK Digital, a Jaykay WOS, received a CDSCO licence to manufacture eight Class C/D orthopaedic and spinal implants. The lifetime licence expands the company's medical devices portfolio.

Execution

Lifetime

Other Announcement

Jaykay Enterprises Other Announcement

Jaykay Enterprises Ltd has submitted its quarterly shareholding pattern report under Regulation 31(1)(b) for the period ended September 30, 2026.

Employee Stock Options

Jaykay Enterprises Employee Stock Options

Jaykay Enterprises granted 13,000 stock options at Rs. 215.01 per option under its 2025 ESOP scheme. Vesting spans three years with a two-year exercise window.

Other AnnouncementReligare Enterprises Ltd RELIGARE

Religare Enterprises Other Announcement

Religare Enterprises filed CARE Ratings' monitoring agency report for the quarter ended September 30, 2026, on its Rs 1,500 crore preferential warrant issue. The report states proceeds were used per the offer document with no deviation.

Other AnnouncementOptivalue Tek Consulting Ltd OPTIVALUE

Optivalue Tek Consulting Other Announcement

Optivalue Tek filed Acuité's half-yearly monitoring report on IPO proceeds for H1 FY2026-27. No deviation from the offer objects was observed.

Other Announcement5Paisa Capital Ltd 5PAISA

5Paisa Capital Other Announcement

5paisa Capital Ltd filed its quarterly shareholding pattern under Regulation 31(1)(c). It reports routine holding figures with no new transaction or corporate event.

Other AnnouncementChennai Meenakshi Multispeciality Hospital Ltd CMMHOSP

Chennai Meenakshi Multispeciality Hospital Other Announcement

Chennai Meenakshi Multispeciality Hospital issued a duplicate share certificate for 100 shares to Inder Chand Kothari L under folio 00008717. The intimation is routine share-certificate paperwork with no transaction or money involved.

Other AnnouncementAxel Polymers Ltd AXELPOLY

Axel Polymers Other Announcement

Axel Polymers reports no deviation in utilisation of its Rs 11.18 Crore preferential issue proceeds for the quarter ended 30 September 2026. This is a routine Regulation 32 statement of deviation with a clean auditor certificate.

Other Announcement360 One Wam Ltd 360ONE

360 One Wam Other Announcement

360 ONE WAM disclosed PIT sales by five insiders on 12 November 2026, totalling about Rs 3.55 Crore. The sellers are designated persons, KMP and an employee's relative, with no promoter involved.

Value

₹3.55 Cr